White cells 2: Impact of understanding the molecular basis of haematological malignant disorders on clinical practice

Lancet

Volumn 355, Issue 9213, 2000, Pages 1447-1453

  Stewart, A K ^a   Schuh, A C ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LEUKEMIA; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BLOOD DISEASE; CHROMOSOME 11Q; CHROMOSOME DELETION 13; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKOCYTE; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSCRIPTION REGULATION; TREATMENT PLANNING;

EID: 0034701475     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02150-4     Document Type: Review

References (57)

1. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:1973;290-293.
2. Kurzrock R., Gutterman J.U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 319:1988;990-998.
3. Veldman T., Vignon C., Schrock E., Rowley J.D., Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet. 15:1997;406-410.
4. Chen Z., Morgan R., Berger C.S., Pearce-Birge L., Stone J.F., Sandberg A.A. Identification of masked and variant Philadelphia(complex type) translocations in CML and classic Ph in AML and ALL by fluorescence in situ hybridization with the use of bcr/abl cosmid probes. Cancer Genet Cytogenet. 70:1993;103-107.
5. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;10792.
6. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med. 340:1999;1330-1340.
7. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
8. Bose S., Deininger M., Gora-Tybor J., Goldman J.M., Melo J.V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals. biologic significance and implications for the assessment of minimal residual disease Blood. 92:1998;3362-3367.
9. Kurzrock R., Estrov Z., Kantarjian H., Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 16:1998;1526-1531.
10. Seong D.C., Kantarjian H.M., Ro J.Y.et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood. 86:1995;2343-2349.
11. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med. 341:1999;164-172.
12. Druker B.J., Tamura S., Buchdunger E.et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566.
13. Grimwade D., Walker H., Oliver F.et al. The importance of diagnostic cytogenetics on outcome in AML. analysis of 1,612 patients entered into the MRC AML 10 trial Blood. 92:1998;2322-2333.
14. Heim S., Mitelman F. Cancer cytogenetics, 2nd edn. 1995;Wiley-Liss, New York.
15. Mrozek K., Heinonen K., de la Chapelle A., Bloomfield C.D. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 24:1997;17-31.
16. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:1990;558-561.
17. Huang M.E., Ye Y.C., Chen S.R.et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:1988;567-572.
18. Lin R.J., Egan D.A., Evans R.M. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15:1999;179-184.
19. He L.Z., Guidez F., Tribioli C.et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 18:1998;126-135.
20. Warrell R.P. Jr. Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia. Int J Cancer. 70:1997;496-497.
21. Miller W.H. Jr., Levine K., DeBlasio A., Frankel S.R., Dmitrovsky E., Warrell R.P. Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood. 82:1993;1689-1694.
22. Golub T.R., Barker G.F., Stegmaier K., Gilliland D.G. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol. 220:1997;67-79.
23. Frank R., Zhang J., Uchida H., Meyers S., Hiebert S.W., Nimer S.D. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 11:1995;2667-2674.
24. Waring P.M., Cleary M.L. Disruption of a homolog of trithorax by 11q23 translocations. leukemogenic and transcriptional implications Curr Top Microbiol Immunol. 220:1997;1-23.
25. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med. 341:1999;1051-1062.
26. Rubnitz J.E., Behm F.G., Downing J.R. 11q23 rearrangements in acute leukemia. Leukemia. 10:1996;74-82.
27. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H. Jr., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:1998;811-814.
28. Grignani F., De Matteis S., Nervi C.et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:1998;815-818.
29. Carapeti M., Aguiar R.C., Goldman J.M., Cross N.C. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 91:1998;3127-3133.
30. Borrow J., Stanton V.P. Jr., Andresen J.M.et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 14:1996;33-41.
31. Taki T., Sako M., Tsuchida M., Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 89:1997;3945-3950.
32. Sobulo O.M., Borrow J., Tomek R.et al. MLL is fused to CBP a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p133). Proc Natl Acad Sci USA. 94:1997;8732-8737.
33. Rubnitz J.E., Downing J.R., Pui C.H.et al. TEL gene rearrangement in acute lymphoblastic leukemia. a new genetic marker with prognostic significance J Clin Oncol. 15:1997;1150-1157.
34. Golub T.R., Slonim D.K., Tamayo P.et al. Molecular classification of cancer. class discovery and class prediction by gene expression monitoring Science. 286:1999;531-537.
35. Kuppers R., Klein U., Hansmann M.L., Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med. 341:1999;1520-1529.
36. Gribben J.G., Neuberg D., Barber M.et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood. 83:1994;3800-3807.
37. Stewart A.K., Schwartz R.S. Immunoglobulin V regions and the B cell. Blood. 83:1994;1717-1730.
38. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1999;1848-1854.
39. Bahler D.W., Levy R. Clonal evolution of a follicular lymphoma. evidence for antigen selection Proc Natl Acad Sci USA. 89:1992;6770-6774.
40. Vallisa D., Berte R., Rocca A.et al. Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med. 106:1999;556-560.
41. Hussell T., Isaacson P.G., Crabtree J.E., Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 178:1996;122-127.
42. Wotherspoon A.C., Doglioni C., Diss T.C.et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 342:1993;575-577.
43. Kuppers R., Hansmann M.L., Rajewsky K. Clonality and germinal centre B-cell derivation of Hodgkin/Reed- Sternberg cells in Hodgkin's disease. Ann Oncol. 9(suppl 5):1998;S17-S20.
44. Kapp U., Yeh W.C., Patterson B.et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 189:1999;1939-1946.
45. Caligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia. a bird of a different feather J Clin Oncol. 17:1999;399-408.
46. Stilgenbauer S., Dohner K., Bentz M., Lichter P., Dohner H. Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol. 76:1998;101-110.
47. Cuneo A., Bigoni R., Rigolin G.M.et al. 13q14 deletion in non-Hodgkin's lymphoma. correlation with clinicopathologic features Haematologica. 84:1999;589-593.
48. Chang H., Bouman D., Boerkoel C.F., Stewart A.K., Squire J.A. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia. 13:1999;105-109.
49. Shaughnessy J., Barlogie B. Chromosome 13 deletion in myeloma. Curr Top Microbiol Immunol. 246:1999;199-203.
50. Taylor A.M., Metcalfe J.A., Thick J., Mak Y.F. Leukemia and lymphoma in ataxia telangiectasia. Blood. 87:1996;423-438.
51. Hallek M., Leif Bergsagel P., Anderson K.C. Multiple myeloma. increasing evidence for a multistep transformation process Blood. 91:1998;3-21.
52. Bergsagel P.L., Nardini E., Brents L., Chesi M., Kuehl W.M. IgH translocations in multiple myeloma. a nearly universal event that rarely involves c-myc Curr Top Microbiol Immunol. 224:1997;283-287.
53. Chesi M., Nardini E., Brents L.A.et al. Frequent translocation t(4;14)(p16. 3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 16:1997;260-264.
54. Fonseca R., Witzig T.E., Gertz M.A.et al. Multiple myeloma and the translocation t(11;14)(q13;q32). a report on 13 cases Br J Haematol. 101:1998;296-301.
55. Chesi M., Bergsagel P.L., Shonukan O.O.et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 91:1998;4457-4463.
56. Plowright E.E., Li Z., Bergsagel P.L.et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 95:2000;992-998.
57. Barlogie B., Jagannath S., Desikan K.R.et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 93:1999;55-65.